SCHEMBL5832263

SCHEMBL5832263

COc1cc(-c2nc3ccccc3o2)ccc1C(C)C#N

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.65
PTGS2 P35354 1/20 0.48
ALOX5 P09917 1/20 0.47
MAPT P10636 7/20 0.47
POLB P06746 2/20 0.47
TDP1 Q9NUW8 1/20 0.47
KDM4E B2RXH2 6/20 0.46
ALDH1A1 P00352 6/20 0.46
HPGD P15428 6/20 0.46
PTPN2 P17706 1/20 0.45
PTPN1 P18031 1/20 0.45
PTPN5 P54829 1/20 0.45
TP53 P04637 4/20 0.45
HSD17B10 Q99714 5/20 0.45
TSHR P16473 3/20 0.45
NPSR1 Q6W5P4 1/20 0.45
SMN1; SMN2 Q16637 3/20 0.44
RAB9A P51151 2/20 0.44
USP2 O75604 2/20 0.44
MEN1 O00255 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30842485 0.87 NPC1 (0.73) NPC1PTGS2ALOX5MAPTPOLB
SCHEMBL13439422 0.87 NPC1 (0.73) NPC1PTGS2ALOX5MAPTPOLB
SCHEMBL5832852 0.86 NPC1 (0.62) NPC1PTGS2ALOX5MAPTPOLB
SCHEMBL5832211 0.84 NPC1 (0.59) NPC1PTGS2ALOX5MAPTPOLB
SCHEMBL5832486 0.81 NPC1 (0.71) NPC1PTGS2ALOX5MAPTPOLB
SCHEMBL28436509 0.80 NPC1 (1.00) NPC1PTGS2ALOX5MAPTPOLB
SCHEMBL5832479 0.78 NPC1 (0.71) NPC1PTGS2ALOX5MAPTPOLB
SCHEMBL660569 0.78 NPC1 (0.67) NPC1PTGS2ALOX5MAPTPOLB
SCHEMBL11699537 0.77 NPC1 (0.55) NPC1MAPTKDM4EALDH1A1HPGD
SCHEMBL5832580 0.77 NPC1 (0.79) NPC1PTGS2ALOX5MAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7087601-B2 Metabotropic glutamate receptor-5 modulators MERCK & CO., INC. (US) 2006-08-08 US disclosed
EP-1453815-A4 METABOTROPIC GLUTAMATE RECEPTOR-5 MODULATORS MERCK & CO INC (US) 2005-04-06 EP disclosed
US-20050065340-A1 Metabotropic glutamate receptor-5 modulators MERCK SHARP & DOHME CORP. 2005-03-24 US disclosed
EP-1453815-A1 METABOTROPIC GLUTAMATE RECEPTOR-5 MODULATORS Merck & Co., Inc. (US) 2004-09-08 EP disclosed
WO-2004030637-A2 TREATMENT OF OBESITY AND OTHER DISORDERS ASSOCIATED WITH EXCESSIVE FOOD INTAKE MERCK & CO., INC. (US) 2004-04-15 WO disclosed
WO-2003048137-A1 METABOTROPIC GLUTAMATE RECEPTOR-5 MODULATORS MERCK & CO., INC. (US) 2003-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050065340-A1 Metabotropic glutamate receptor-5 modulators GRM5, GRIK5, GRM1 NPC1 3080/4885PTGS2 1019/4885ALOX5 229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.